InvestorsObserver
×
News Home

SPAC Vesper (VSPR) Shares Slide, Replimune Group (REPL) Rises After Clinical Trial Updates 

Wednesday, May 05, 2021 02:32 PM | Slav Kandyba

Mentioned in this article

SPAC Vesper (VSPR) Shares Slide, Replimune Group (REPL) Rises After Clinical Trial Updates 

What’s going on with VSPR?

The stock of Vesper Healthcare Acquisition Co. (VSPR), the SPAC backing Replimune Group (REPL), dipped 3.07% after Replimune issued a clinical update for two clinical trials. Shares of VSPR were trading at $12.65 per share on Wednesday afternoon, while REPL shares were up 8.67% to $35.35.

Replimune provided updates for CERPASS, its Phase 2 clinical trial of a therapy for cutaneous squamous cell carcinoma, and for IGNYTE, a single arm clinical trial for the treatment of anti-PD1 failed melanoma. 

What does this mean for Vesper?

VSPR shares dipped after Replimune Group’s update on the two key clinical trials, although the company maintains its guidance to release initial data in 2022 and announced plans to submit the amended CERPASS clinical trial protocol to the U.S. Food and Drug Administration in the first half of this year. 

RP1, Replimune’s lead Immulytic platform-based potential product, is based on a unique new strain of herpes simplex virus. It’s being investigated in combination with Libtayo, a treatment being developed by Regeneron and Sanofi. 

“Based on the depth and durability of responses and the manageable safety profile we have seen in patients with non-melanoma skin cancers treated with RP1 in combination with Opdivo to date, we are amending the clinical trial protocol for our Phase 2 CERPASS clinical trial to include complete response (CR) rate as a primary endpoint in addition to overall response rate (ORR), and to reduce target enrollment to 180 patients,” said Robert Coffin, Ph.D., President and Chief Research and Development Officer of Replimune.   

With respect to IGNYTE, Replimune recently held a Type B meeting with the FDA to go over the proposed 125-patient, single-arm cohort in the IGNYTE clinical trial. It is currently enrolling patients with anti-PD1 failed cutaneous melanoma, and the FDA expressed that while a randomized controlled trial would always be preferred to support licensure, that in this population if the data generated is sufficiently compelling, then the data could be considered for submission by the FDA under the accelerated approval pathway.

“The discussion with the FDA at the Type B meeting provides clarity on the appropriate regulatory pathway to potential approval for RP1 in combination with Opdivo in anti-PD1 failed melanoma based on the data intended to be generated from our ongoing clinical trial. We look forward to releasing initial data from this study during 2022,” Coffin said.

Sentiment Score - ,bullish

Vesper Healthcare Acquisition Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VSPR!

Vesper Healthcare Acquisition Corp is a blank check company.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App